Protection of bone in premenopausal women with breast cancer: Focus on zoledronic acid

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 569-576

  Aft, Rebecca ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Premenopausal; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CLODRONIC ACID; DENOSUMAB; ESTROGEN; GOSERELIN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE PROTECTION; BONE REMODELING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PREMENOPAUSE; PROTECTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREATMENT RESPONSE;

EID: 84870505022     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S29101     Document Type: Review

References (66)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588-1594.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-593.
4. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2008;34(2):183-192.
5. Weinfurt KP, Li Y, Castel LD, etal. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579-584.
6. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. Available from: http://www.nof.org. Accessed 4 April 2012.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
8. Eastell R, Adams JE, Coleman RE, etal. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051-1057.
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, etal; for Austrian Breast and Colorectal Cancer Study Group (ABSCG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840-849.
10. Shapiro CL, Halabi S, Hars V, etal. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011;47(5):683-689.
11. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24(4):675-680.
12. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69(1):73-82.
13. Zometa®(zoledronic acid) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
14. Aredia®(pamidronate) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
15. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15(3):955-962.
16. Fuleihan GE, Salamoun M, Mourad YA, etal. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90(6):3209-3214.
17. Hershman DL, McMahon DJ, Crew KD, etal. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26(29):4739-4745.
18. Hershman DL, McMahon DJ, Crew KD, etal. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab. 2010;95(2):559-566.
19. Kim JE, Ahn JH, Jung KH, etal. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat. 2011;125(1):99-106.
20. Powles TJ, McCloskey E, Paterson AH, etal. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90(9):704-708.
21. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12(9):1358-1367.
22. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets. 2009;9(5):626-638.
23. Kavanagh KL, Guo K, Dunford JE, etal. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103(20):7829-7834.
24. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119(Suppl 2):S150-S162.
25. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-589.
26. Monkkonen H, Auriola S, Lehenkari P, etal. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006;147(4):437-445.
27. Xgeva®(denosumab) [package insert]. Thousand Oaks, CA: Amgen Inc; 2010.
28. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;3:CD003474.
29. Food and Drug Administration Center for Drug Evaluation and Research. Oncologic Drugs Advisory Committee Meeting: March 4, 2005. Aredia/Zometa. Available from: www.fda.gov. Accessed 4 April 2012.
30. Rosen LS, Gordon D, Kaminski M, etal. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
31. Stopeck AT, Lipton A, Body JJ, etal. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
32. Van Poznak CH, Temin S, Yee GC, etal. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221-1227.
33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®Breast Cancer. Version 1. 2012.
34. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15(4):1341-1347.
35. Cummings SR, San Martin J, McClung MR, etal. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
36. Ellis GK, Bone HG, Chlebowski R, etal. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875-4882.
37. Black DM, Delmas PD, Eastell R, etal; for HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
38. Brufsky AM, Harker WG, Beck JT, etal. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192-1201.
39. Eidtmann H, de Boer R, Bundred N, etal. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188-2194.
40. Llombart A, Frassoldati A, Paija O, etal. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40-48.
41. Hines SL, Mincey BA, Sloan JA, etal. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol. 2009;27(7):1047-1053.
42. Gnant M. Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? Curr Oncol Rep. 2012;14(1):35-43.
43. Gnant MF, Kaura S, Sofrygin O, Delea TE. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer (BC) enrolled in the ABCSG-12study [poster]. Presented at: IMPAKT-Breast Cancer Conference; May 7-9, 2009; Brussels, Belgium. Abstract 73P.
44. Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011;29(8):533-541.
45. Thurston SJ, Zelt SC, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) for the treatment of bone loss in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the United States (US). J Clin Oncol. 2010;28(Suppl):Abstract e11007.
46. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008; 34(5):453-475.
47. Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M. Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases [poster]. Presented at: 2011ASCO Breast Cancer Symposium; September 8-10, 2011; San Francisco, CA. Abstract 151.
48. Candelaria-Quintana D, Dayao ZR, Royce ME. The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer. Breast Cancer Res Treat. 2012;132(2):355-363.
49. Gnant M, Mlineritsch B, Schippinger W, etal; for ABSCG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
50. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, etal. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor-positive early breast cancer [oral]. Presented at: 2011 CTRC-AACR San Antonio Breast Cancer Symposium; December 6-10, 2011; San Antonio, TX. Abstract S1-S2.
51. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14(9):2519-2526.
52. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22(5):941-950.
53. Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis. J Pathol. 2010;222(1):1-15.
54. Aft R, Naughton M, Trinkaus K, etal. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11(5):421-428.
55. Lin AY, Park JW, Scott J, etal. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol. 2008;26(Suppl):20s. Abstract 559.
56. Rack B, Juckstock J, Genss EM, etal. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30(5):1807-1813.
57. Solomayer EF, Gebauer G, Hirnle P, etal. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]. Presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2048.
58. Kim MY, Oskarsson T, Acharyya S, etal. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315-1326.
59. Coleman RE, Marshall H, Cameron D, etal; for AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-1405.
60. Gnant M, Mlineritsch B, Stoeger H, etal; for Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631-641.
61. Hoff AO, Toth BB, Altundag K, etal. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23(6):826-836.
62. Ripamonti CI, Maniezzo M, Campa T, etal. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137-145.
63. Badros A, Terpos E, Katodritou E, etal. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26(36):5904-5909.
64. Coleman R, Bundred N, de Boer R, etal. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 4082.
65. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010;16(9):693-702.
66. Zhou Z, Redaelli A, Johnell O, Willke RJ, Massimini G. A retrospective analysis of health care costs for bone fractures in women with early-stage breast carcinoma. Cancer. 2004;100(3):507-517.